- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00066547
Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination Chemotherapy
An Open Label Phase I/II Study of Humanized Human Milk Fat Globule-1 (THEREX) in Patients With Locally Advanced or Metastatic Breast Cancer Following Prior Anthracycline and Taxane Therapy
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
PURPOSE: Phase I/II trial to study the effect of monoclonal antibody therapy on the body and its effectiveness in treating women who have locally advanced or metastatic breast cancer that was previously treated with combination chemotherapy.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
OBJECTIVES:
- Determine the safety and tolerability of monoclonal antibody HuHMFG1 in women with locally advanced or metastatic breast cancer previously treated with anthracycline and taxane-based therapy.
- Determine the maximum tolerated dose and appropriate schedule of this drug in these patients.
- Determine the pharmacokinetic profile of this drug in these patients.
- Determine the tumor response rate, progression-free survival, and median survival of patients treated with this drug.
- Analyze immunological markers for evaluation of disease status (e.g., in vitro analysis of antibody-dependent cellular cytotoxicity, natural killer cell activity, complement depletion, and tumor markers CA 15.3 and CEA) in patients treated with this drug.
OUTLINE: This is a dose-escalation, open-label, nonrandomized, multicenter study.
- Phase I: Patients receive monoclonal antibody HuHMFG1 IV over 1-3 hours once every 3 weeks for doses 1 and 2. All subsequent dose intervals are based on individual half-life value of the drug. Patients receive at least 6 doses in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of monoclonal antibody HuHMFG1 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
- Phase II:Patients receive monoclonal antibody HuHMFG1 as above at the MTD. Patients are followed at 28 days.
PROJECTED ACCRUAL: Approximately 3-40 patients (3-15 patients for phase I and 19-25 patients for phase II) will be accrued for this study within approximately 12 months.
Undersøgelsestype
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
California
-
Los Angeles, California, Forenede Stater, 90095-1781
- Jonsson Comprehensive Cancer Center, UCLA
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed breast cancer
- Locally advanced or metastatic disease
- No inflammatory breast cancer
- Polymorphic epithelial mucin (PEM) antigen overexpression by immunohistochemistry
Previously treated with an anthracycline and a taxane in any combination for breast cancer
- No more than 2 prior chemotherapy regimens, including adjuvant /neoadjuvant therapy
- No more than 1 prior regimen for distant metastatic disease
- Any number of prior hormonal or biologic therapy regimens allowed
Measurable disease
- At least one unidimensionally measurable lesion not previously irradiated
The following are not considered measurable lesions:
- Bone
- Leptomeningeal disease
- Ascites
- Pleural/pericardial effusion
- Lymphangitis cutis/pulmonis
- Abdominal masses not confirmed and followed by imaging techniques
- Cystic lesions
- No metastases accessible to complete surgical resection
- No CNS metastasis by CT scan
Hormone receptor status:
- Not specified
PATIENT CHARACTERISTICS:
Age
- 18 and over
Sex
- Female
Menopausal status
- Not specified
Performance status
- WHO 0-2
Life expectancy
- At least 4 months
Hematopoietic
- Hemoglobin at least 10 g/dL
- Neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
Hepatic
- Bilirubin no greater than 1.5 mg/dL
- ALT and AST no greater than 2.5 times upper limit of normal (ULN) (less than 5 times ULN if liver metastases are present)
Renal
- Creatinine no greater than 1.5 times ULN OR
- Creatinine clearance greater than 60 mL/min
- No hyperuricemia (uric acid at least 1.25 times ULN)
- No hypercalcemia (calcium at least 11.5 mg/dL [corrected for serum albumin])
Cardiovascular
- LVEF at least 45% by MUGA or echocardiogram within the past 4 weeks
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3-6 months after study participation
- No other prior malignancy within the past 5 years except adequately treated nonmelanoma skin cancer or cervical intraepithelial neoplasia
- No other concurrent uncontrolled comorbid illness that represents unacceptable risk in the opinion of the investigator
- No legal incapacity
PRIOR CONCURRENT THERAPY:
Biologic therapy
- See Disease Characteristics
- More than 2 weeks since prior growth factors to aid hematologic recovery
- No other concurrent immunotherapy
Chemotherapy
- See Disease Characteristics
- More than 4 weeks since prior cytotoxic chemotherapy
- No concurrent chemotherapy for metastatic breast cancer
Endocrine therapy
- See Disease Characteristics
- No concurrent endocrine therapy for metastatic breast cancer
- No concurrent chronic corticosteroid therapy
- No concurrent high-dose corticosteroids
Radiotherapy
- More than 4 weeks since prior radiotherapy except for palliation
- No concurrent antitumor radiotherapy except for palliation
Surgery
- More than 4 weeks since prior major surgery
Other
- More than 2 weeks since prior blood transfusions to aid hematologic recovery
- No participation in any other investigational drug study
- No other concurrent investigational drugs
- No other concurrent antitumor therapy
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Maskning: Ingen (Åben etiket)
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Mark D. Pegram, MD, Jonsson Comprehensive Cancer Center
Datoer for undersøgelser
Studer store datoer
Studiestart
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CDR0000316264
- UCLA-0212097
- ANTISOMA-TOPCAT
- ANTISOMA-ASM-THEREX-01
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Brystkræft
-
Cairo UniversityIkke rekrutterer endnu
-
Abouqir General HospitalAlexandria UniversityRekrutteringBreast Udseende Rekonstruktion DisproportionEgypten
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbejdspartnereAfsluttetDen kliniske anvendelsesvejledning af Conebeam Breast CTKina
-
ETOP IBCSG Partners FoundationAfsluttetBreast Cancer Invasive NosItalien
-
Spanish Breast Cancer Research GroupHoffmann-La Roche; Roche Farma, S.AAfsluttetBreast Cancer Invasive NosSpanien
-
Ontario Clinical Oncology Group (OCOG)Afsluttet
-
Pomeranian Medical University SzczecinMaria Sklodowska-Curie National Research Institute of Oncology; Regional...UkendtBRCA1 mutation | Breast Cancer Invasive NosPolen
-
Aga Khan UniversityAfsluttetBrystkræft | Perforatorklap | Brysttumor | Oncoplasty | Breast-QPakistan
-
University Health Network, TorontoAfsluttetBreast Cancer Invasive Nos | Primær invasiv brystkræftCanada
-
KU LeuvenNovartisUkendtER Positive, HER2 Negative Breast Cancer NeoplasmaBelgien
Kliniske forsøg med monoklonalt antistof HuHMFG1
-
Université de SherbrookeAfsluttetFor tidlig fødselCanada
-
Centre hospitalier de l'Université de Montréal...Fonds de la Recherche en Santé du QuébecAfsluttetAktive eller tidligere injektionsbrugere | Indikation af hepatitis C-screeningCanada
-
University of SouthamptonWest Hertfordshire Hospitals NHS TrustAfsluttet
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)AfsluttetBrystkræftForenede Stater
-
Vachira Phuket HospitalRekruttering
-
Baxalta now part of ShireAfsluttetRefraktær ovariecancer med tilbagevendende symptomatisk malign ascitesForenede Stater
-
Institut de Médecine et d'Epidémiologie Appliquée...Gilead Sciences; Roche Pharma AG; ANRS, Emerging Infectious Diseases; BioMé... og andre samarbejdspartnereAfsluttetHepatitis B | Carcinom, hepatocellulært | Hepatitis C | HIV | AIDSFrankrig
-
Sun Yat-sen UniversityChipscreen Biosciences, Ltd.Ikke rekrutterer endnuTilbagefaldende eller refraktær DLBCL
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI); Actinium PharmaceuticalsAfsluttetLeukæmi | Myelodysplastisk syndromForenede Stater
-
Antisoma ResearchAfsluttetBrystkarcinomDen Russiske Føderation